Currently Viewing:
American Society of Hematology
Currently Reading
Ibrutinib More Effective Than Stem-Cell Transplant in Patients With Form of Chronic Leukemia
December 07, 2017
Significant Economic Burden Associated With Various AML Treatment Episodes
December 08, 2017
The Effects of Myeloproliferative Neoplasm Symptoms on Quality of Life
December 08, 2017
Using Time Spent at Home to Measure End-of-Life Care Quality
December 09, 2017
Treatment-Free Remission and Preventing Cardiotoxicity: The Future of CML Care
December 10, 2017
Single-Agent Ibrutinib Promising in MCL and CLL, Improves Patient Well-Being
December 10, 2017
Dr Kerry Rogers: Ibrutinib's Impact on Vaccine Response
December 10, 2017
Dr Derek Raghavan Outlines Challenges to Implementing Evidence-Based Guidelines
December 10, 2017
Balancing Hospice Utilization With the Need for Transfusion in Leukemia
December 11, 2017
CTL019 More Cost Effective in Pediatric Patients With Acute Lymphoblastic Lymphoma
December 11, 2017
Clonal Expansion and Aging Fuel the Development of Neoplasms, Say Experts at ASH
December 11, 2017
Dr Nina Shah on the Benefits of Outpatient HSCT When Possible
December 11, 2017
Dr Thomas LeBlanc: Patients With Blood Cancers Less Likely to Use Hospice Care
December 11, 2017
CAR T Progress: Global Submissions for Kymriah, 42% Ongoing Response With Yescarta in ZUMA-1 Patients
December 11, 2017
Dr Joshua Richter Discusses Patient Financial Burden of New Treatments and Cures
December 12, 2017
Dr Julie Wolfson Highlights Different Outcomes in AYAs With ALL Compared With Children
December 12, 2017
New Treatment Paradigm Supersedes ABVD in Advanced Hodgkin Lymphoma: The ECHELON-1 Study
December 12, 2017
Dr Stephen Schuster Outlines CAR T Results Seen in Leukemia, Lymphoma, and Myeloma
December 12, 2017
Diagnosing Non-Chemotherapy Drug-Induced Neutropenia
December 16, 2017
Care Utilization Patterns in Sickle Cell Disease: Managing Pain and Care Transitions in AYAs
December 18, 2017
New Drug Approvals in Leukemia and Lymphoma Presented at ASH 2017
December 18, 2017
Dr Derek Raghavan: Ensuring Guidelines Are Implemented and Followed
December 22, 2017
Diagnosing Congenital Neutropenia
December 23, 2017
Dr Shannon Maude Discusses Side Effects of CAR T Therapies
December 25, 2017

Dr Derek Raghavan Addresses the Concept of "Cookbook Medicine"

While clinicians can have a bad reaction to the idea of “cookbook medicine,” it can really result in patients getting the best treatment, said Derek Raghavan, MD, PhD, FACP, FRACP, president, Carolinas HealthCare System's Levine Cancer Institute.
 


While clinicians can have a bad reaction to the idea of “cookbook medicine,” it can really result in patients getting the best treatment, said Derek Raghavan, MD, PhD, FACP, FRACP, president, Carolinas HealthCare System's Levine Cancer Institute.

Transcript

Implementing evidence-based guidelines can be viewed as “cookbook medicine.” Is the concept of what cookbook medicine means and can do changing?

The phrase “cookbook medicine” is sort of an unhappy one because it triggers reactions, particularly among clinicians who like to individualize care. And they make it seem like the creativity of medicine is going out the window. My own feeling is, if you use the term “cookbook medicine,” simply to relate to a concept where you have structured evidence with the best level of clinical trial data that has been looked at by both leaders in the medical community and isolated clinicians to ensure that whatever the “recipe” is can be implemented well, then I think that has to lead to better medicine.

It’s pretty much the same as true cooking. You’ll have the most brilliant culinary chef who has days when his creativity just doesn’t work. Hopefully, the best of the chefs actually, are using the tricks that they’ve used again, and again successfully. Every now and then an experiment in the kitchen fails abysmally and if it happens to be at a major function, it’s catastrophic for the cook. From the medicine analogy, when you make a mistake it’s much more catastrophic for the patient.

So, today, patients have the right to expect the best treatment, the cheapest treatment, based on the evidence that’s available that has been published by independent clinicians, not necessarily people with a conflict of interest. Once you develop guidelines that are predicated on level 1 evidence with people who don’t have skin in the game and that have been reviewed independently, patients are likely to get better results.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up